GlassScriptPhysician profile
Anthony Allemon
NPI 1760133003
$5,393.44
in general payments reported to CMS, 2019-2025
33 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $547 · 2023: $1,531 · 2024: $1,880 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,623 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,622.97 |
| Education | $223.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $882.28 | 2022-2025 | |
| Janssen Biotech, INC. | $552.70 | 2023-2025 | Erleada, Balversa, Akeega |
| Myriad Genetic Laboratories, INC. | $533.07 | 2023-2025 | Prolaris |
| Antares Pharma, INC. | $419.76 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Urogen Pharma, INC. | $333.23 | 2023-2025 | Jelmyto |
| Endo USA, INC. | $312.36 | 2024-2025 | Xiaflex |
| Pfizer INC. | $303.37 | 2022-2025 | |
| Coloplast Corp | $243.89 | 2023-2024 | Speedicath |
| Bayer Healthcare Pharmaceuticals INC. | $238.37 | 2023-2025 | |
| Astellas Pharma US INC | $220.51 | 2024-2025 | Xtandi |
| Progenics Pharmaceuticals, INC. | $204.45 | 2022-2025 | Pylarify |
| Blue Earth Diagnostics | $183.68 | 2022-2025 | Posluma |
| Merck Sharp & Dohme LLC | $162.34 | 2022-2024 | Keytruda, Welireg, Lynparza |
| 180 Medical, INC. | $113.50 | 2024 | |
| Sumitomo Pharma America, INC. | $93.96 | 2023-2025 | Gemtesa, Orgovyx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $92.79 | 2025 | Illuccix |
| Immunitybio, INC. | $74.57 | 2025 | |
| Halozyme INC | $55.27 | 2023 | |
| Boston Scientific Corporation | $37.17 | 2024 | Rezum Generator |
| Sun Pharmaceutical Industries INC. | $35.96 | 2022 | |
| Ferring Pharmaceuticals INC. | $29.28 | 2025 | Adstiladrin |
| Becton, Dickinson and Company | $28.68 | 2024 | Bard Urinary Drainage Bag |
| C. R. Bard, INC. & Subsidiaries | $27.26 | 2025 | Bard Urinary Drainage Bag |
| Novartis Pharmaceuticals Corporation | $26.56 | 2025 | |
| Acerus Pharmaceuticals Corporation | $24.75 | 2022 | |
| Caris Mpi, INC. | $24.32 | 2025 | Mi Cancer Seek |
| Axonics, INC. | $22.97 | 2024 | Axonics |
| Procept Biorobotics Corporation | $21.87 | 2025 | |
| Olympus America INC. | $21.07 | 2025 | Uropass |
| Kowa Pharmaceuticals America, INC. | $18.85 | 2023 | Seglentis |
| Endo Pharmaceuticals INC. | $18.73 | 2023 | Xiaflex |
| Tolmar, INC. | $18.11 | 2023 | |
| Angiodynamics, INC. | $17.76 | 2025 | Nanoknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Allemon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.